Comparative Pharmacology
Head-to-head clinical analysis: ACETADOTE versus PRALIDOXIME CHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACETADOTE versus PRALIDOXIME CHLORIDE.
ACETADOTE vs PRALIDOXIME CHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Acetylcysteine serves as a precursor to glutathione, replenishing hepatic glutathione stores and enhancing the detoxification of the toxic metabolite N-acetyl-p-benzoquinoneimine (NAPQI) in acetaminophen overdose.
Pralidoxime chloride is a cholinesterase reactivator. It reactivates acetylcholinesterase that has been inactivated by phosphorylation due to organophosphate or carbamate exposure by binding to the organophosphate moiety and cleaving the enzyme-phosphate bond, thereby restoring enzymatic activity. It also has direct antimuscarinic and antinicotinic effects at high doses.
Intravenous loading dose of 150 mg/kg over 60 minutes, then 50 mg/kg over 4 hours, then 100 mg/kg over 16 hours (total 300 mg/kg over 21 hours). Oral: 140 mg/kg loading dose, then 70 mg/kg every 4 hours for 17 doses.
1-2 g IV over 15-30 minutes, may repeat in 1 hour if muscle weakness persists, then every 10-12 hours as needed; typically given with atropine. Maximum dose: 2 g/hour or 12 g/day.
None Documented
None Documented
Terminal elimination half-life: 5.6 hours (range 4.1-7.6). In acetaminophen overdose, half-life may be prolonged (up to 20 hours) due to saturation of metabolic pathways.
Terminal elimination half-life is approximately 1.5–2.5 hours in adults. In renal impairment, half-life may be prolonged up to 5–6 hours, necessitating dose adjustment.
Renal: 60-80% as unchanged drug and metabolites (sulfate, glucuronide, cysteine, N-acetylcysteine conjugates). Fecal: minor (less than 3%).
Renal: >90% as unchanged drug and metabolites (including pyridone and pyridinium derivatives). Biliary/fecal: <5%.
Category C
Category C
Antidote
Antidote